SYNDAX PHARMACEUTICALS, INC. | |||||
(unaudited) | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
March 31, | December 31, | ||||
(In thousands) | 2019 | 2018 | |||
Cash, cash equivalents, short-term and long-term investments | $ 92,742 | $ 80,911 | |||
Total assets | $ 99,392 | $ 83,938 | |||
Total liabilities | $ 30,766 | $ 30,891 | |||
Total stockholders' equity (deficit) | $ 68,626 | $ 53,047 | |||
Common stock outstanding | 27,095,779 | 24,835,951 | |||
Common stock and common stock equivalents* | 41,819,938 | 31,088,934 | |||
*Common stock and common stock equivalents: | |||||
Common stock | 27,095,779 | 24,835,951 | |||
Common stock warrants (pre-funded) | 4,500,000 | 2,000,000 | |||
Common stock and pre-funded stock warrants | 31,595,779 | 26,835,951 | |||
Options to purchase common stock | 5,629,120 | 4,252,983 | |||
Common stock warrants (series 1 and 2) | 4,595,039 | - | |||
Total common stock and common stock equivalents | 41,819,938 | 31,088,934 | |||
SYNDAX PHARMACEUTICALS, INC. | |||||
(unaudited) | |||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||
Three Months Ended March 31, | |||||
(In thousands, except share and per share data) | 2019 | 2018 | |||
License fee revenue | $ 379 | $ 379 | |||
Operating expenses: | |||||
Research and development | 11,279 | 15,339 | |||
General and administrative | 3,911 | 4,791 | |||
Total operating expenses | 15,190 | 20,130 | |||
Loss from operations | (14,811) | (19,751) | |||
Other income, net | 509 | 353 | |||
Net loss | $ (14,302) | $ (19,398) | |||
Net loss attributable to common stockholders | $ (14,302) | $ (19,398) | |||
Net loss per share attributable to common | |||||
stockholders--basic and diluted | $ (0.53) | $ (0.79) | |||
Weighted-average number of common stock | |||||
used to compute net loss per share attributable | |||||
to common stockholders--basic and diluted | 27,023,466 | 24,478,269 | |||
